{
    "2020-10-14": [
        [
            {
                "time": "",
                "original_text": "贝达药业(300558.SZ)：前三季净利预增145%至175%",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "净利",
                        "预增",
                        "145%",
                        "175%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业前三季盈利4.86亿元~5.46亿元，投资收益贡献近半利润",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "盈利",
                        "投资收益",
                        "利润"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：前三季度预计净利润同比增长145.0%~175.0%",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "净利润",
                        "同比增长",
                        "145.0%",
                        "175.0%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业(300558.SZ)预计前三季度归母净利润同比上升145%至175%",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "归母净利润",
                        "同比上升",
                        "145%",
                        "175%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "新股前瞻丨加科思：王印祥离开贝达药业（300558.SZ）后的底气",
                "features": {
                    "keywords": [
                        "加科思",
                        "王印祥",
                        "离开",
                        "贝达药业",
                        "底气"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业2020三季度业绩前瞻：板块分化明显 医疗服务等板块有序复苏",
                "features": {
                    "keywords": [
                        "医药生物",
                        "2020",
                        "三季度",
                        "业绩",
                        "板块分化",
                        "医疗服务",
                        "复苏"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "医疗服务"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}